(Q36579819)

15 August 2017

1 reference

title

The systemic safety of inhaled corticosteroid therapy: a focus on ciclesonide (English)

1 reference

15 August 2017

1

Eli O Meltzer

1 reference

15 August 2017

2

Hartmut Derendorf

1 reference

15 August 2017

publication date

1 August 2006

1 reference

Annals of Allergy, Asthma & Immunology

15 August 2017

published in

1 reference

15 August 2017

volume

97

1 reference

15 August 2017

issue

2

1 reference

15 August 2017

page(s)

149-157

1 reference

Review of the unique properties of budesonide

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

1 reference

7 January 2021

Evaluation of efficacy and safety of flunisolide hydrofluoroalkane for the treatment of asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Placebo-controlled, comparative study of the efficacy and safety of triamcinolone acetonide inhalation aerosol with the non-CFC propellant HFA-134a in patients with asthma. Azmacort HFA Clinical Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

A controlled trial of chlorofluorocarbon-free triamcinolone acetonide inhalation aerosol in the treatment of adult patients with persistent asthma. Azmacort HFA Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Diskus and diskhaler: efficacy and safety of fluticasone propionate via two dry powder inhalers in subjects with mild-to-moderate persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Improvement of asthma control with beclomethasone extrafine aerosol compared to fluticasone and budesonide

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Improved safety with equivalent asthma control in adults with chronic severe asthma on high-dose fluticasone propionate

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Efficacy of HFA-beclomethasone dipropionate extra-fine aerosol (800 microg day(-1)) versus HFA-fluticasone propionate (1000 microg day(-1)) in patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Once-daily mometasone furoate dry powder inhaler in the treatment of patients with persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Efficacy and safety of budesonide inhalation powder (Pulmicort Turbuhaler) during 52 weeks of treatment in adults and children with persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Inhaled budesonide for adults with mild-to-moderate asthma: a randomized placebo-controlled, double-blind clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Effectiveness of low doses (50 and 100 microg b.i.d) of beclomethasone dipropionate delivered as a CFC-free extrafine aerosol in adults with mild to moderate asthma. Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

The local side effects of inhaled corticosteroids: current understanding and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Side effects of inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Potential adverse effects of the inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Inhaled corticosteroids: past lessons and future issues

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Effects of inhaled corticosteroids on bone.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Adverse effects of inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Bone mineral density and the risk of fracture in patients receiving long-term inhaled steroid therapy for asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Systemic adverse effects of inhaled corticosteroid therapy: A systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Osteocalcin, growth, and inhaled corticosteroids: a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Association of inhaled corticosteroid use with cataract extraction in elderly patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Systemic effects of inhaled corticosteroids in children

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Bone mineral density in women with asthma on long-term inhaled corticosteroid therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Improved airway targeting with the CFC-free HFA-beclomethasone metered-dose inhaler compared with CFC-beclomethasone

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Influence of particle size on lung deposition and pharmacokinetics of beclomethasone dipropionate in children

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Systemic effect comparisons of six inhaled corticosteroid preparations

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Ultrafine particle deposition in subjects with asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane-beclomethasone extrafine inhalation aerosol), in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Effects of HFA- and CFC-beclomethasone dipropionate on the bronchial response to methacholine (MCh) in mild asthma.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Fluticasone propionate plasma concentration and systemic effect: effect of delivery device and duration of administration

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Hydrofluoroalkane-134A beclomethasone or chlorofluorocarbon fluticasone: effect on small airways in poorly controlled asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Pharmacokinetic and pharmacodynamic properties of inhaled corticosteroids in relation to efficacy and safety

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Pharmacokinetics and pharmacodynamics of inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Sense and sensitivity: assessing inhaled corticosteroid effects on the hypothalamic-pituitary-adrenal axis

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Pharmaceutical characteristics that influence the clinical efficacy of inhaled corticosteroids

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

In vitro and in vivo anti-inflammatory activity of the new glucocorticoid ciclesonide

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Formation of fatty acid conjugates of ciclesonide active metabolite in the rat lung after 4-week inhalation of ciclesonide

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

1 reference

7 January 2021

Pharmacokinetics of [14C]ciclesonide after oral and intravenous administration to healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Population pharmacokinetics and pharmacodynamics of ciclesonide.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Adrenal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Glucocorticoid-induced adrenal insufficiency

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Therapeutic ratio of inhaled corticosteroids in adult asthma. A dose-range comparison between fluticasone propionate and budesonide, measuring their effect on bronchial hyperresponsiveness and adrenal cortex function

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Suppression and recovery of adrenal response after short-term, high-dose glucocorticoid treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

A low dose ACTH test to assess the function of the hypothalamic-pituitary-adrenal axis.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Comparison of the Low Dose Short Synacthen Test (1 g), the Conventional Dose Short Synacthen Test (250 g), and the Insulin Tolerance Test for Assessment of the Hypothalamo-Pituitary-Adrenal Axis in Patients with Pituitary Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Short-term lower-leg growth rate and urine cortisol excretion in children treated with ciclesonide

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5'monophosphate in asthmatic patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Ciclesonide, a novel inhaled steroid, does not affect hypothalamic-pituitary-adrenal axis function in patients with moderate-to-severe persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Effect of ciclesonide and fluticasone on hypothalamic-pituitary-adrenal axis function in adults with mild-to-moderate persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Suppression of hypothalamic-pituitary-adrenal axis activity with inhaled flunisolide and fluticasone propionate in adult asthma patients

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Once-daily ciclesonide 80 or 320 microg for 12 weeks is safe and effective in patients with persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Airway and systemic effects of hydrofluoroalkane formulations of high-dose ciclesonide and fluticasone in moderate persistent asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

Dynamic Modeling of Cortisol Reduction after Inhaled Administration of Fluticasone Propionate

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2960005-1

7 January 2021

10.1016/S1081-1206(10)60005-1

Identifiers

DOI

1 reference

15 August 2017

1 reference